Our study demonstrated that the PD-1/L1 immune checkpoint inhibitors combined with bevacizumab in combination with platinum-containing two-drug chemotherapy were effective in patients with advanced NSCLC after resistance to EGFR-TKIs, in whom survival was better than that in patients receiving conventional platinum-containing two-drug chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.